Detalhe da pesquisa
1.
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Haematologica;
2023 Nov 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38031804
2.
Cost-effectiveness of gene-expression profiling for tumor-site origin.
Value Health;
16(1): 46-56, 2013.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23337215
3.
Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.
Int Rev Psychiatry;
25(5): 509-33, 2013 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24151799
4.
Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
Leuk Lymphoma;
64(14): 2269-2278, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37840271
5.
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Lancet Haematol;
9(4): e289-e300, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35358443
6.
Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings.
J Int Assoc Physicians AIDS Care (Chic);
8(4): 253-68, 2009.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19721103
7.
Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry.
Arthritis Care Res (Hoboken);
68(12): 1888-1893, 2016 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27111064
8.
Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.
Rheumatol Ther;
3(1): 103-115, 2016 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27747515
9.
Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
Arthritis Res Ther;
17: 256, 2015 Sep 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26382589
10.
Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population.
Rheumatol Ther;
2(1): 85-96, 2015 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27747494
11.
Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry.
J Rheumatol;
42(7): 1090-8, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25934829
12.
Health Care Coverage Decision Making in Low- and Middle-Income Countries: Experiences from 25 Coverage Schemes.
Popul Health Manag;
18(4): 265-71, 2015 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25393442
13.
Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.
Leuk Lymphoma;
53(2): 225-34, 2012 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21824050
14.
Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy.
Leuk Lymphoma;
53(12): 2371-7, 2012 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22591119
15.
Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.
Adv Ther;
27(11): 763-73, 2010 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20931365